Archit Organosys reported a 59% year-on-year increase in net profit for FY26, reaching ₹803.21 lakh. The chemical manufacturer saw total income grow by 11.77% to ₹14,383.71 lakh, reflecting improved operational performance and cost management.

The Board of Directors has recommended a final dividend of ₹1 per equity share, representing a 10% payout on the face value of ₹10. This marks a step-up from the previous year’s dividend of ₹0.50 per share.

Financial Performance

Revenue from operations stood at ₹14,095.25 lakh for the fiscal year ended March 31, 2026, compared to ₹12,559.92 lakh in FY25. The company managed to expand its profit before tax (PBT) to ₹1,099.25 lakh, up from ₹753.89 lakh in the prior year.

Operating costs rose to ₹13,055.64 lakh from ₹11,857.33 lakh, while financial expenses declined slightly to ₹228.82 lakh from ₹257.98 lakh.

What the Numbers Show

The divergence between revenue growth and profit expansion indicates improved operating leverage. While top-line growth was modest at 11.77%, the bottom line accelerated significantly due to a combination of lower financial costs and controlled operational expenses relative to income. The effective tax rate decreased to 26.93% from 33.00% in the previous year, further supporting the net profit margin expansion.

Corporate Governance and Strategy

The company’s paid-up equity share capital remained unchanged at ₹20.52 crore. During the year, there were changes in key managerial personnel, with Anilkumar G. Patel appointed as Chief Financial Officer and Chirag Chouhan as Company Secretary.

The Board highlighted confidence in future performance, citing opportunities in the specialty chemicals boom and expanding export markets. The company continues to focus on technology absorption and energy conservation to maintain competitive advantage in the chemical manufacturing sector.

Archit Organosys Limited has scheduled a Board of Directors meeting for September 3, 2026. The agenda includes evaluating proposals to raise capital through equity shares or other permissible securities.

The company disclosed the meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board may consider issuing equity shares, share warrants, or other equity-based instruments through a preferential issue on a private placement basis.

Any such issuance is subject to receipt of relevant approvals as may be required by the Board and regulatory authorities. The company did not disclose the specific amount or purpose of the proposed fundraising in the intimation.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window has been closed for Promoters, Directors, Senior Managerial Personnel, along with their immediate relatives and other connected persons.

The window will reopen after the expiry of 48 hours from the time the event becomes generally available. This restriction applies until the details of the board meeting outcomes are made public.

Corporate Governance

Kandarp Amin, Chairman and Whole-time Director, signed the intimation letter dated August 27, 2026. The communication was addressed to BSE Limited, requesting the exchange to take the information on record.